Cialis image

New possibility for Lilly erectile drug

pharmafile | September 24, 2012 | News story | Sales and Marketing CHMP, Cialis, ED, hyperplasia, lilly 

Eli Lilly’s erectile disfunction (ED) brand Cialis has been recommended to treat benign prostatic hyperplasia (BPH) in Europe.

If the European Commission accepts the CHMP’s positive opinion, the new addition to Cialis (tadalafil)’s licence means it will be the first single treatment option in Europe for both complaints (ED+BPH).

BPH, a condition in which the prostate enlarges and can cause urinary symptoms, often occurs in men with ED, and Cialis 5mg has already been approved in the US for both ED and ED+BPH.

“The CHMP positive opinion for Cialis marks an important regulatory milestone for Eli Lilly and Co and our commitment to bringing new treatment options to the millions of men who experience ED and BPH,” said Anthony Beardsworth, senior medical director at Lilly.

Advertisement

There are various brands on the market for either condition, such as Abbott Laboratories’ Hytrin (terazosin HCl) for BPH and Vivus’ Stendra (avanafil) and Pfizer’s Viagra (sildenafil) for ED.

The Commission is likely to give its verdict within two months. It approved Cialis in ED ten years ago, and gave the green light for its once-daily use in 2007.

The drug has already got the nod for BPH in a dozen other countries including Canada, Mexico, Brazil, South Korea and Russia and is approved in ED in more than 100 countries worldwide.

Adam Hill

Related Content

Bristol Myers Squibb receives positive CHMP opinion for Opdivo treatment

Bristol Myers Squibb (BMS) has received a positive opinion from the Committee for Medicinal Products …

NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE

BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute …

Eplontersen recommended for EU approval by CHMP for treatment of hereditary transthyretin-mediated amyloidosis

Wainzua (eplotersen), produced by AstraZeneca and Ionis, has been recommended for approval in the European …

The Gateway to Local Adoption Series

Latest content